Composition for inhibiting skin aging

The composition using 2-deoxy-D-glucose targets melanocyte glycolysis to address skin aging, restoring melanosome transport and reducing senescence-related phenotypes, effectively delaying skin aging by inhibiting melanocyte aging.

WO2024232499A1PCT designated stage expired Publication Date: 2024-11-14AJOU UNIV IND ACADEMIC COOP FOUND
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2024/000823
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-09
Filing Date
2024-01-17
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

Current compositions for inhibiting skin aging primarily focus on dermal fibroblasts, while the role of melanocytes in skin aging remains understudied, particularly their contribution to UV-induced senescence and hypopigmentation, with existing solutions not addressing the glycolysis process in melanocytes.

Method used

A composition containing 2-deoxy-D-glucose as a glycolysis inhibitor to target and inhibit the aging of melanocytes by restoring the melanosome transport process and reducing senescence-related secretory phenotypes, thereby delaying skin aging.

Benefits of technology

The use of 2-deoxy-D-glucose effectively inhibits glycolysis in melanocytes, restoring melanosome transport and reducing aging markers, leading to delayed skin aging and improved melanocyte function.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2024000823_14112024_PF_FP_ABST
    Figure KR2024000823_14112024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to a composition containing 2-deoxy-D-glucose as an active ingredient for inhibiting skin aging.
Need to check novelty before this filing date? Find Prior Art

Description

Composition for preventing skin aging

[0001] The present invention relates to a composition for inhibiting skin aging.

[0002] Senescent cells accumulate in various tissues, including the skin, during the aging process and contribute to skin functional decline through the senescence-associated secretory phenotype (SASP), characterized by the secretion of pro-inflammatory factors. Most studies have focused on the dermal compartment, and fibroblasts are considered the primary cell type responsible for skin aging. However, little is known about the role of melanocytes in aging.

[0003] Recent studies have highlighted the expression of aging markers by melanocytes and their accumulation in aged skin, and indeed, melanocytes appear to be the primary senescent cells of the epidermis. Senescent melanocytes have been observed in middle-aged, light-exposed skin and, unlike senescent fibroblasts, which are observed regardless of age, their number increases sequentially with age.

[0004] Several studies have suggested that senescent melanocytes can induce the activation of skin aging. Specifically, senescent melanocytes can contribute to skin aging by influencing neighboring cells through paracrine telomere dysfunction in keratinocytes and fibroblasts. Furthermore, these cells are expected to be involved in the pathogenic processes that lead to hypopigmentation. Indeed, p16INK4A-expressing melanocytes have been found in hypopigmented aged skin, such as idiopathic guttate hypomelanosis (IGH) and perilesional vitiligo.

[0005] Differences in molecular mechanism alterations between different cell types undergoing aging provide potential cell type-specific targets for aging modulation. Given their specific role in ultraviolet (UV) protection, melanocytes are likely to undergo exceptional changes during aging. Therefore, a better understanding of the molecular characteristics of melanocytes aged under chronic UV exposure will provide a new mechanistic basis for understanding the aging process.

[0006] The inventors of the present invention investigated the functional characteristics and molecular mechanisms underlying aging in UV-irradiated melanocytes, and as a result, confirmed that melanosome transport process was significantly dysfunctional in UV-induced senescent melanocytes (UVSM) and melanocytes of hypopigmented aged skin, and confirmed that this process was linked to melanocyte aging, and completed the present invention regarding a composition for inhibiting skin aging based on this.

[0007] The background technology of this application, Republic of Korea Patent Publication No. 10-1520037, relates to a composition for inhibiting skin aging, comprising an MMP-1 (matrix metalloprotease-1) inhibitor as an active ingredient. While the patent discloses inhibiting skin aging by inhibiting MMP-1, it does not disclose inhibiting skin aging by inhibiting the glycolytic process of melanocytes.

[0008] The present invention aims to solve the problems of the above-mentioned prior art and provides a composition for inhibiting skin aging that includes a process inhibitor as an active ingredient.

[0009] However, the technical tasks to be achieved by the embodiments of the present invention are not limited to the technical tasks described above, and other technical tasks may exist.

[0010] As a technical means for achieving the above-mentioned technical task, the first aspect of the present invention aims to provide a composition for inhibiting skin aging, which comprises 2-deoxy-D-glucose as an active ingredient.

[0011] According to one embodiment of the present invention, the 2-deoxy-D-glucose may delay skin aging by inhibiting aging of melanocytes in the skin, but is not limited thereto:

[0012] According to one embodiment of the present invention, the 2-deoxy-D-glucose may inhibit glycolysis, but is not limited thereto.

[0013] According to one embodiment of the present invention, a defect in the melanosome transport process may be recovered by inhibiting the corresponding process, but is not limited thereto.

[0014] According to one embodiment of the present invention, the 2-deoxy-D-glucose may increase the expression of a melanosome transport-related gene selected from the group consisting of MYO5A, RAB27A, MLPH, and combinations thereof, but is not limited thereto.

[0015] According to one embodiment of the present invention, the 2-deoxy-D-glucose may reduce the expression of a cellular senescence-related gene selected from the group consisting of CDKN2A, CDKN1A, and combinations thereof, but is not limited thereto.

[0016] According to one embodiment of the present invention, the 2-deoxy-D-glucose may reduce the expression of a senescence-associated secretory phenotype (SASP) selected from the group consisting of, but not limited to, IL-6, MMP1, IGFBP7, and combinations thereof.

[0017] According to one embodiment of the present invention, the composition for inhibiting skin aging may additionally include a pharmaceutically acceptable carrier, but is not limited thereto.

[0018] According to one embodiment of the present invention, the carrier may include, but is not limited to, a group consisting of lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, menthol, mineral oil, and combinations thereof.

[0019] According to one embodiment of the present invention, the composition for inhibiting skin aging may further include, but is not limited to, an ingredient selected from the group consisting of a preservative, a solubilizer, a stabilizer, a humectant, a sweetener, a colorant, a flavoring agent, a salt, a buffer, an antioxidant, a lubricant, an emulsifier, a suspending agent, a preservative, and combinations thereof.

[0020] According to one embodiment of the present invention, the composition for inhibiting skin aging may be administered by a method selected from the group consisting of intraperitoneal administration, oral administration, inhalation administration, intravenous administration, intramuscular administration, subcutaneous administration, dermal administration, intrauterine administration, tumor administration, rectal administration, and combinations thereof, but is not limited thereto.

[0021] In addition, the second aspect of the present invention aims to provide a health functional food comprising a composition for inhibiting skin aging according to the first aspect of the present invention.

[0022] The above-described problem-solving methods are merely exemplary and should not be construed as limiting the present invention. In addition to the exemplary embodiments described above, additional embodiments may be included in the drawings and detailed description of the invention.

[0023] The composition for inhibiting skin aging according to the present invention comprises 2-deoxy-2-glucose, known as a glycolysis inhibitor, as an active ingredient, and the glycolysis of melanocytes in the skin is inhibited by the 2-deoxy-2-glucose, thereby recovering a defect in the melanosomal transport process of the melanocytes, thereby inhibiting aging of the melanocytes and delaying skin aging.

[0024] However, the effects that can be obtained from this center are not limited to the effects described above, and other effects may exist.

[0025] Hereinafter, the description of Sham in the drawing refers to normal melanocytes as a control group, and the description of UVSM refers to UV-irradiated aged melanocytes.

[0026] Figure 1 shows an example of a normal primary melanocyte irradiation treatment at 60 mJ / cm according to one embodiment of the present invention. 2 This is the result of analyzing cell senescence using SA-β-Gal staining after culturing for 10 days following 4 consecutive days of UVB irradiation.

[0027] Figure 2 shows the result of heterochromatin foci formation according to one embodiment of the present invention.

[0028] Figure 3 shows the results of p16INK4A / p21Waf1 mRNA expression levels according to one example of the present invention.

[0029] Figure 4 shows the melanin content and tyrosinase activity level of UVB-induced aged melanocytes according to one embodiment of the present invention.

[0030] Figure 5 shows the results of similarity and differential gene expression profiling of control and UVB-induced aged melanocytes detected by RNA sequencing analysis according to one embodiment of the present invention (top) and the results of mRNA expression levels of SASP analyzed by real-time PCR (bottom).

[0031] Figure 6 shows the results of performing GSEA (Gene Set Enrichment Analysis) using the “FRIDMAN aging”, “KEGG melanin production”, and “GOBP melanocyte differentiation” gene sets according to one embodiment of the present invention, demonstrating the sequential transition of gene expression from Sham to UVSM.

[0032] Figure 7 shows the results of analyzing MITF (Microphthalmia-associated transcriptant factor) mRNA and tyrosinase mRNA using real-time polymerase chain reaction (qPCR) and western blotting after irradiating normal primary melanocytes with UVB and culturing them for 10 days according to one example of the present invention.

[0033] Figure 8 shows the results of analyzing MITF protein and tyrosinase protein using qPCR and Western blotting after irradiating normal primary melanocytes with UVB and culturing them for 10 days according to one example of the present invention.

[0034] Figure 9 shows the results of electron microscopic analysis of Sham and UVSM according to one embodiment of the present invention (wherein '1' and '2' represent fields observed at higher magnification, and 'N' and 'C' represent the nucleus and cytoplasm, respectively) and the results of analyzing the total number of melanosomes and melanosomal distribution.

[0035] Figure 10 shows the results of IHC analysis of p16INK4A and MART1 performed on a series of sections from an IGH patient according to one embodiment of the present invention. Here, arrows indicate p16INK4A-positive melanocytes.

[0036] Figure 11a shows the results of an electron microscopy analysis of an IGH patient skin sample according to one embodiment of the present invention, and Figure 11b shows the results of an electron microscopy analysis using UVSM. In Figure 11a, 'M', 'K', and the red line represent melanocytes, keratinocytes, and melanocyte boundaries, respectively, and in Figure 11b, the arrows represent abnormal mitochondria.

[0037] Figure 12 is a schematic diagram of the melanosome transport process in melanocytes.

[0038] Figure 13 is a heatmap showing the log2(-fold) change in the expression levels of kinesin and dynein obtained from mRNA sequencing (sham vs. UVSM) according to one embodiment of the present invention.

[0039] Figure 14 shows the results of analyzing the level of melanosome-transfer tripartite complex gene expression using mRNA sequencing, qPCR, and Western blotting according to one embodiment of the present invention.

[0040] Figure 15 shows the results of single cell transcriptome data divided into six different sub-clusters, called cluster 1 (C1) to cluster 6 (C6), according to the elapsed pseudotime after normal primary melanocytes were irradiated with UVB and cultured for 10 days according to one embodiment of the present invention.

[0041] Figure 16 is a result of aging module score using the “FRIDMAN aging” gene set according to one embodiment of the present invention.

[0042] Figure 17 shows the results of MITF, TYR and CDKN2A mRNA expression levels in a single cell cluster according to one embodiment of the present invention (upper left panel) and the results of GSEA performed to demonstrate that gene expression levels sequentially transition from C2 to C4 and from C4 to C5 using the “FRIDMAN aging”, “KEGG melanogenesis” and “GOBP melanocyte differentiation” gene sets (upper and lower right panels).

[0043] Figure 18 is a violin plot showing the expression levels of aging-related genes (CDKN2A, CDKN1A, TP53), melanosome transport-related genes (MYO5A, RBA27A, MLPH), and melanin production-related genes (MITF, TYR, TYRP1) encoding mRNA according to one embodiment of the present invention.

[0044] Figure 19 is a schematic diagram of gene expression changes in a single cell cluster.

[0045] Figure 20 is a result of gene ontology analysis of differentially expressed genes between C4 and C5 according to one embodiment of the present invention.

[0046] Figure 21 shows the results of gene expression related to the corresponding process in a single cell cluster according to one embodiment of the present invention.

[0047] Figure 22 is a schematic diagram showing the mechanism by which the corresponding process and the corresponding process inhibitor work (left) and the results of a violin plot analysis of the expression levels of genes related to the corresponding process between C4 and C5 (right).

[0048] FIG. 23 is a result of performing GSEA to demonstrate sequential transition of gene expression levels from C4 to C5 using the “CELLULAR RESPIRATION”, “HALLMARK HYPOXIA” and “HALLMARK GLYCOLYSIS” gene sets according to one embodiment of the present invention.

[0049] Figure 24 shows the results of glucose uptake and lactate production in Sham and UVSM according to one embodiment of the present invention.

[0050] Figure 25 shows the results of analyzing SA-β-Gal staining and mRNA expression after irradiating normal melanocytes with UVB according to one embodiment of the present invention and maintaining them in a low- or high-glycemic culture medium for 5 days.

[0051] Figure 26 is a schematic diagram (top) of a treatment schedule for a process inhibitor (2-DG) according to one embodiment of the present invention, and the results of analyzing glucose absorption and lactic acid production according to the presence or absence of 2-DG treatment (bottom).

[0052] Figure 27 shows the results of CDKN1A and CDKN2A mRNA expression levels according to the presence or absence of 2-DG treatment according to one embodiment of the present invention.

[0053] Figure 28 shows the results of SASP mRNA expression levels according to the presence or absence of 2-DG treatment according to one embodiment of the present invention.

[0054] Figure 29 shows the results of SA-β-Gal staining according to the presence or absence of 2-DG treatment according to one example of the present invention.

[0055] Figure 30 shows the results of mRNA expression of melanosome transport-related genes (MYO5A, RAB27A, and MLPH) depending on the presence or absence of 2-DG treatment according to one example of the present invention.

[0056] Figure 31 shows the results of mRNA expression of melanin production-related genes (MITF and TYR) depending on the presence or absence of 2-DG treatment according to one example of the present invention.

[0057] Figure 32 shows the results of total melanin content according to the presence or absence of 2-DG treatment according to one embodiment of the present invention.

[0058] Figure 33 shows the results of electron microscopy analysis of UVSM and 2-DG-treated UVSM according to one embodiment of the present invention (top) and the results of analysis of melanosome distribution (bottom).

[0059] Figure 34 shows the results of the mRNA expression levels of genes related to glucose uptake, lactate production, aging (CDKN1A and CDKN2A), melanin transport (MYO5A, RAB27A and MLPH) and melanin production (MITF and TYR) in Sham and UVSM with or without AZ67 treatment according to one embodiment of the present invention.

[0060] Below, with reference to the attached drawings, embodiments of the present invention are described in detail to facilitate easy implementation by those skilled in the art. However, the present invention can be implemented in various different forms and is not limited to the embodiments described herein. In the drawings, irrelevant parts have been omitted for clarity, and similar reference numerals have been used throughout the specification to indicate similar elements.

[0061] Throughout this specification, when a part is said to be "connected" to another part, this includes not only cases where it is "directly connected" but also cases where it is "electrically connected" with another element in between.

[0062] Throughout this specification, when it is said that a member is located “on,” “above,” “upper,” “lower,” “lower” or “lower” another member, this includes not only cases where the member is in contact with the other member, but also cases where another member exists between the two members.

[0063] Throughout this specification, whenever a part is said to "include" a component, this does not mean that it excludes other components, but rather that it may include other components, unless otherwise specifically stated.

[0064] The terms "about," "substantially," and the like, as used herein, are used to mean at or near the numerical value when manufacturing and material tolerances inherent to the meanings referred to are presented, and are used to prevent unscrupulous infringers from unfairly exploiting disclosures that contain precise or absolute numerical values ​​to aid understanding of the present disclosure. Furthermore, throughout the present disclosure, the terms "step of ~" or "step of ~" do not mean "step for ~."

[0065] Throughout this specification, the term "combination thereof" included in the expressions in the Makushi format means one or more mixtures or combinations selected from the group consisting of the components described in the expressions in the Makushi format, and means including one or more selected from the group consisting of said components.

[0066] Throughout this specification, references to “A and / or B” mean “A, B, or A and B.”

[0067] Hereinafter, the composition for inhibiting skin aging of this invention will be described in detail with reference to embodiments, examples, and drawings. However, this invention is not limited to these embodiments, examples, and drawings.

[0068]

[0069] As a technical means for achieving the above-mentioned technical task, the first aspect of the present invention aims to provide a composition for inhibiting skin aging, which comprises 2-deoxy-D-glucose as an active ingredient.

[0070] According to one embodiment of the present invention, the 2-deoxy-D-glucose may delay skin aging by inhibiting aging of melanocytes in the skin, but is not limited thereto:

[0071] According to one embodiment of the present invention, the 2-deoxy-D-glucose may inhibit glycolysis, but is not limited thereto.

[0072] According to one embodiment of the present invention, a defect in the melanosome transport process may be recovered by inhibiting the corresponding process, but is not limited thereto.

[0073] According to one embodiment of the present invention, the 2-deoxy-D-glucose may increase the expression of a melanosome transport-related gene selected from the group consisting of MYO5A, RAB27A, MLPH, and combinations thereof, but is not limited thereto.

[0074] According to one embodiment of the present invention, the 2-deoxy-D-glucose may reduce the expression of a cellular senescence-related gene selected from the group consisting of CDKN2A, CDKN1A, and combinations thereof, but is not limited thereto.

[0075] According to one embodiment of the present invention, the 2-deoxy-D-glucose may reduce the expression of a senescence-associated secretory phenotype (SASP) selected from the group consisting of, but not limited to, IL-6, MMP1, IGFBP7, and combinations thereof.

[0076] According to one embodiment of the present invention, the composition for inhibiting skin aging may additionally include a pharmaceutically acceptable carrier, but is not limited thereto.

[0077] According to one embodiment of the present invention, the carrier may include, but is not limited to, a group consisting of lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, menthol, mineral oil, and combinations thereof.

[0078] According to one embodiment of the present invention, the composition for inhibiting skin aging may further include, but is not limited to, an ingredient selected from the group consisting of a preservative, a solubilizer, a stabilizer, a humectant, a sweetener, a colorant, a flavoring agent, a salt, a buffer, an antioxidant, a lubricant, an emulsifier, a suspending agent, a preservative, and combinations thereof.

[0079] According to one embodiment of the present invention, the composition for inhibiting skin aging may be administered by a method selected from the group consisting of intraperitoneal administration, oral administration, inhalation administration, intravenous administration, intramuscular administration, subcutaneous administration, dermal administration, intrauterine administration, tumor administration, rectal administration, and combinations thereof, but is not limited thereto.

[0080] In addition, the second aspect of the present invention aims to provide a health functional food comprising a composition for inhibiting skin aging according to the first aspect of the present invention.

[0081] Regarding the health functional food according to the second aspect of this application, detailed descriptions of parts that overlap with the first aspect of this application have been omitted, but even if the descriptions have been omitted, the contents described in the first aspect of this application may be equally applied to the second aspect of this application.

[0082] The present invention will be described in more detail through the following examples; however, the following examples are for illustrative purposes only and are not intended to limit the scope of the present invention.

[0083]

[0084] [Example 1]

[0085] cell culture

[0086] Primary normal human melanocytes (HEMn-M P, Gibco, C1025C) at passages 3-7 were cultured in Medium-254 (M254; Gibco) supplemented with human melanocyte growth supplement (HMGS; Gibco).

[0087]

[0088] In vitro model of senescent melanocytes

[0089] For UV-irradiated senescent melanocytes (UVSM), primary human melanocytes were washed once with Dulbecco's Phosphate Buffered Saline (DPBS) containing calcium chloride and magnesium chloride (Gibco) and placed in fresh DPBS. Cells were exposed to 60 mJ / cm2 for 4 consecutive days using an LZC-1 photoreactor system (Luzchem Research Inc, Ontario, Canada). 2 Irradiated with UVB (peak maximum 313 nm).

[0090] After irradiation, cells were maintained for 10 days in F12 medium (Gibco, Thermo Fisher Scientific, Waltham, MA) supplemented with 10% heat-inactivated fetal bovine serum (FBS; Gibco), 1% penicillin / streptomycin (Gibco), 24 μg / ml 3-isobutyl-1-methylxanthine (Sigma, St. Louis, MO), 1.2 ng / ml basic fibroblast growth factor (Sigma, St. Louis, MO), and 0.1 μg / ml cholera toxin (List Biological, Campbell, CA).

[0091]

[0092] Senescence associated β-galactosidase (SA-β-Gal) staining

[0093] Cells were fixed with 4% formalin for 15 min and then incubated with SA-β-Gal solution (X-gal, 1 mg / ml; citric acid / sodium phosphate, pH 5.8, 40 mM; potassium ferrocyanide, 5 mM; potassium ferricyanide, 5 mM; NaCl, 150 mM; and MgCl2, 2 mM) at 37°C for 12 h. After washing with PBS, SA-β-Gal-positive cells were analyzed by light microscopy.

[0094]

[0095] Heterochromatin foci analysis

[0096] For heterochromatin foci analysis, cells were fixed with 4% paraformaldehyde for 15 min at room temperature. Cells were stained with 4′,6-diamidino-2-phenylindole (DAPI) for 10 min, and heterochromatin foci were analyzed using a fluorescence microscope (Axiovert 200M, Carl Zeiss Macroscopy GmbH, Jana, Germany) at the Ajou University 3D Immunosystem Imaging Core Facility.

[0097]

[0098] Real-time polymerase chain reaction (qPCR) analysis

[0099] Total cellular RNA was extracted using the RNeasy Mini kit (Qiagen, Hilden, Germany), and cDNA was obtained using the SuperScript III Reverse Transcriptase Kit (Invitrogen). Real-time PCR was performed in iQ SYBR Green Supermix (Bio-Rad) at the following conditions: initial activation at 95°C for 5 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min.

[0100] The primers used in real-time PCR are as follows.

[0101] human 18S: 5'-CGGCTACCACATCCAAGGAA-3' and 5'-GCTGGAATTACCGCGGCT-3';

[0102] MITF: 5'-AGAACAGCAACGCGCAAAAGAAC-3' and 5'-ATGATCCGATTCACCAAATCTG-3';

[0103] tyrosinase: 5'-CACCACTTGGGCCTCAATTTC-3' and 5'-AAAGCCAAACTTGCAGTTTCCAC-3';

[0104] p16INK4A: 5'-GAGCAGCATGGAGGCCTTC-3' and 5'-GGCCTCCGACCGTAACTATT-3';

[0105] p21Waf1: 5'-AGGTGGACCTGGAGACTCTCAG-3' and 5'-TCCTCTTGGAGAAGATCAGCCG-3';

[0106] Myosin 5A: 5'-AGTCTCTGTGTCGTTCATTCG-3' and 5'-CCTGTATGTAAACTCACGGTA-3';

[0107] RAB27A: 5'-TGGAGGACCAGAGAGTAGTGAAA-3' and 5'-AGTTTCAAAGTAGGGGATTCCA-3';

[0108] MLPH: 5'-GCCCATCAAACCAACAGACA-3' 및 5'-TCCTCTGGTCTCTTGCCAAG-3';

[0109] IL-1β: 5'-AAATACCTGTGGCCTTGGGC-3' 및 5'-TTTGGGATCTACACTCTCCAGCT-3';

[0110] IL-6: 5'-CCACACAGACAGCCACTCAC-3' 및 5'-AGGTTGTTTTCTGCCAGTGC-3';

[0111] MMP1: 5'-AAGCGTGTGACAGTAAGCTA-3' 및 5'-AACCGGACTTCATCTCTG-3';

[0112] MMP3: 5'-GGACAAAGGATACAACAGGGACCA-3' 및 5'-GAACCGAGTCAGGTCTGTGAGTG-3';

[0113] IL-8: 5'-ATGACTTCCAAGCTGGCCGTGGCT-3' 및 5'-TCTCAGCCCTCTTCAAAAACTTCT-3';

[0114] IGFBP7: 5'-GGCATGGAGTGCGTGAAGAG-3' 및 5'-CTTGCTGACCTGGGTGATGG-3';

[0115] CCL2: 5'-CTCTGCCGCCCTTCTGTG-3' 및 5'-TGCATCTGGCTGAGCGAG-3';

[0116] CCL3: 5'-TGCAACCAGTTCTCTGCATC-3' 및 5'-AATCTGCCGGGAGGTGTA-3';

[0117] CCL20: 5'-ATGTGCTGTACCAAGAGTTT-3' 및 5'-CAAGTCTGTTTTGGATTTGC-3';

[0118] CCL8: 5'-ATGACTTCCAAGCTGGCCGTGGCT-3' 및 5'-TCTCAGCCCTCTTCAAAAACTTCT-3';

[0119] CXCL1: 5'-AGCTTGCTCAATCCTGCAT-3' and 5'-CCTCTGCAGCTGTGTCTCTC-3';

[0120] CCL5: 5'-ATGAAGGTCTCCGCGGCAGC-3' and 5'-CTAGCTCATCTCCAAAGAGT-3'

[0121]

[0122] Western blotting

[0123] Cells were lysed in RIPA buffer (1% NP-40; 150 mM NaCl; 10 mM Tris-HCl, pH 8.0; and 1 mM EDTA) supplemented with complete protease inhibitors (Sigma). Proteins were separated on SDS-polyacrylamide gels and transferred to polyvinylidene fluoride membranes (Millipore, Burlington, MA). Antibodies against MITF (ab12037) and RAB27 (ab55667) were purchased from Abcam (Cambridge, United Kingdom). Tyrosinase (sc7833) was purchased from Santacruz Biotechnology (Dallas, TX); myosin 5A (NBP2-93397) was obtained from Novus Biologicals (Centennial, CO); and MLPH was purchased from proteintech (Chicago, IL).

[0124]

[0125] Melanin content and tyrosinase activity

[0126] Melanocytes were lysed in 0.1 M phosphate buffer (pH 6.8) containing 1% Triton X-100 and a protease inhibitor cocktail (Roche, Basel, Switzerland). The supernatant was measured to determine the protein concentration using the Lowry assay system. The pellet was dissolved in 100 μL of 1 N NaOH for 3 h at 60°C, and the absorbance was measured at 490 nm to determine the melanin content against a standard curve using synthetic melanin (Sigma). For tyrosinase activity analysis, each sample was incubated with 2 mM L-DOPA (Sigma) in 0.1 M phosphate buffer (pH 6.8) at 37°C for 90 min. After incubation, tyrosinase activity was measured at 490 nm using an ELISA reader (Bio-Rad, Hercules, CA).

[0127]

[0128] electron microscope observation

[0129] Samples were dehydrated in a series of ethanol solutions, infiltrated with propylene oxide, embedded in an Epon mixture (Polysciences, PA, USA), and sequentially incubated at 60°C for 24 h. Sample blocks were sectioned using an ultramicrotome (Reichert-Jung, Bayreuth, Germany). For contrast staining, sections were stained with 6% uranyl acetate (Electron Microscopy Sciences, PA) for 20 min and lead citrate (Thermo Fisher Scientific) for 10 min. Images were obtained using a SIGMA500 transmission electron microscope (Carl Zeiss Microscopy GmbH, Jena, Germany) at the Ajou University 3D Immune System Imaging Core Facility.

[0130]

[0131] Immunohistochemistry (IHC)

[0132] Immunohistochemistry was performed on paraffin-embedded sections fixed in 4% paraformaldehyde. Tissue sections (4 μm) were deparaffinized and rehydrated in xylene and ethanol baths. The sections were then incubated in 0.05% trypsin in Tris-buffered saline for 20 min at 37°C for antigen retrieval. The primary antibodies used were as follows: anti-MART-1 (MS-799-P, dilution 1:100; Neomarker, Fremont, CA) to visualize melanocytes, and anti-p16INK4A rabbit monoclonal antibody (1:100, 725-4713; Ventana Medical Systems, Inc., Oro Valley, AZ) to visualize senescent cells.

[0133]

[0134] Single-cell transcriptome analysis

[0135] Single-cell suspensions were obtained from live UV-stimulated melanocytes as described above. Single-cell RNA sequencing was performed using the Chromium Single Cell 3' V3 Reagent kit (10X Genomics, Pleasanton, CA) according to the manufacturer's protocol. Next-generation sequencing was performed on 10,000 cells per sample using the Illumina HiSeq X Ten System (San Diego, CA USA). Sequencing results were converted to FASTQ files using Cell Ranger (10X Genomics). Samples were aligned using the human genome GRCh38 as a reference. The matrix was loaded into Seurat (v. 3) for data analysis, and R (v. 3.6.1) was used for statistical analysis. Cells with RNA counts below 200 or with mitochondrial gene expression exceeding 15% were excluded. Data were normalized using the NormalizeData function. Variations in gene expression were identified using the FindVariableFeature function. Data dimensionality was reduced to 20 significant PCs for each sample using principal component analysis (PCA). Data were clustered using the FindNeighbors and FindClusters functions at various resolutions. RunUMAP was used to visualize the selected PCs. Data were aligned and normalized for gene counts per cell and mitochondrial gene content using the Seurat workflow. Cluster markers were identified using the FindMarkers function. Pseudotime trajectory calculations were performed using Monocle3 (v. 0.2.3.0), with ribosomal genes removed from the gene expression matrix.

[0136]

[0137] Gene set enrichment analysis (GSEA)

[0138] GSEA was performed using GSEA v. 4.3.2 software. Ranking data were extracted from all differentially expressed genes (DEGs) between Sham and UVSM in bulk RNA sequencing. For single-cell analysis data, DEGs with log2(FC) ≥ 0.25 were used as ranking data. All gene set files for this analysis were obtained from the molecular signature database on the GSEA website (http: / www.gsea-msigdb.org / gsea / msigdb). Enrichment scores (ES), normalized ES (NES), and adjusted P-values ​​were extracted for each gene set after 1,000-fold permutation, and enrichment maps were visualized to illustrate the GSEA results.

[0139]

[0140] Analysis of the corresponding flux (Glycolytic flux)

[0141] Intracellular glycolytic flux was quantitatively estimated by measuring glucose uptake and lactate excretion in cell culture medium. Conditioned medium from normal melanocytes and UVSM cells was collected, and the concentrations of glucose and lactate in the medium were measured using a YSI 7100 MBS Multiparameter Biochemistry Analyzer (YSI Inc., Yellow Springs, OH) according to the manufacturer's instructions. Additionally, the concentration of fresh F12, not incubated with cells, was measured to calculate changes in glucose and lactate concentrations during intracellular metabolic processes.

[0142]

[0143] Inhibition of this process

[0144] To inhibit this process, primary human melanocytes were treated with 0.5 mM 2-deoxy-D-glucose (2-DG; Sigma, St. Louis, MO) or 10 nM AZ67 (Tocris Bioscience, Bristol, UK) before (day 0) and during UVB irradiation (days 1, 2, 3, and 4). Cells were maintained in F12 medium and re-treated with 2-DG or AZ67 after UV irradiation (days 6, 8, 10, and 12) before harvest (day 14).

[0145]

[0146] Statistical analysis

[0147] Data are expressed as the mean ± standard deviation (SD) of independent measurements and were analyzed using the Mann-Whitney U test, with a P value < 0.05 considered significant. IBM SPSS version 25 (IBM, Armonk, NY) was used for all statistical analyses.

[0148]

[0149] [Example 2]

[0150] UV exposure induces aging of melanocytes.

[0151] To understand the molecular characteristics of senescent melanocytes, we designed a UV-induced aging model using isolated normal primary human melanocytes. Melanocytes were exposed to 60 mJ / cm 2 The cells were treated with UVB once daily for 4 consecutive days and maintained for 10 days before evaluation. The UV-irradiated melanocytes showed a significant increase in SA-β-gal staining, a representative aging marker, and in the formation of age-related dyschromatic lesions (Figs. 1 and 2).

[0152] Cellular senescence was further investigated by assessing cell growth rate, and more specifically, the expression levels of the cell cycle regulators CDKN2A and CDKN1A, which encode cyclin-dependent kinase inhibitors. Significant induction of CDKN2A and CDKN1A was observed in UV-irradiated melanocytes (Fig. 3).

[0153] Previous reports have shown that increased melanin content and expression of the senescence-associated secretory phenotype (SASP) are hallmarks of senescent melanocytes. Indeed, increased melanin content was observed in UV-irradiated melanocytes (UVSM) (Fig. 4, right graph).

[0154] Additionally, the transcriptome profile of UV-irradiated melanocytes showed a completely different gene expression profile from the control group (Sham) with increased mRNA expression levels of genes encoding SASP factors (particularly IL-6, MMP1, CCL2, CXCL1, CCL2, and CCL8) (Fig. 5).

[0155] Considering all these results, it was confirmed that continuous UV exposure induces melanocyte senescence. Melanin content significantly increased in UVSM, as shown in Figure 4 (right graph), but the transcriptome profile of UVSM showed lower expression levels of gene sets during melanogenesis and melanocyte differentiation compared to the control group (Figure 6). Furthermore, tyrosinase activity did not increase in UVSM compared to the control group (left graph of Figure 4).

[0156] Example 2 confirmed that the increased melanin content observed in UVSM was not due to increased melanin synthesis but rather to a different mechanism.

[0157]

[0158] [Example 3]

[0159] Aging melanocytes not only exhibit increased melanin content without increased melanin production, but also exhibit excessive melanosome accumulation due to defects in melanosome transport.

[0160] To elucidate the functional properties of UVSM, we assessed the expression of key genes and proteins involved in melanogenesis. While UVSM significantly increased melanin content, the mRNA expression levels of MITF and TYR were significantly downregulated in UVSM (Fig. 7). This was confirmed at the protein level, along with reduced levels of MITF and tyrosinase in UVSM (Fig. 8).

[0161] To investigate the discrepancy between decreased melanin production and increased melanin content, electron microscopic evaluations were performed in the control (Sham) and UVSM cells. As expected, the total number of melanosomes increased in UVSM cells (Fig. 9). However, the distribution of melanosomes differed significantly between the control and UVSM cells. The number of melanosomes near the nucleus (<1 μm from the nucleus) was significantly increased in UVSM cells (Fig. 9), suggesting a defect in melanosome transport in senescent melanocytes.

[0162] The inventors of this paper confirmed these findings in vivo in skin biopsies from donors with idiopathic guttate hypomelanosis (IGH). Senescent melanocytes are a hallmark of IGH, and p16INK4A-positive senescent melanocytes were frequently identified in IGH skin (Fig. 10).

[0163] Electron microscopic analysis revealed that in normal skin, melanosomes were primarily located in the peripheral dendritic region of melanocytes. However, IGH melanocytes exhibited shorter dendrites and perinuclear aggregation of melanosomes (Fig. 11a). In addition to the different melanosomal distributions, UVSM revealed abnormal mitochondrial morphology, a hallmark of senescent cells (Fig. 11b).

[0164] Melanosomal transport dysfunction can occur during the process of excessive melanosome accumulation in UVSM. Several types of movement-related genes, including kinesin and dynein, are involved in melanin transport (Figure 12), and RNA sequencing data show downregulation of these genes in UVSM (Figure 13).

[0165] However, the most important protein for transporting melanin to melanocyte dendrites is a trimeric complex composed of MYO5A, RAB27A, and MLPH. Downregulation of the expression levels of these three genes (MYO5A, RAB27A, and MLPH) was observed in UVSM. This was confirmed by Western blot analysis, along with significant decreases in Myo5a, Rab27a, and MLPH protein levels (Fig. 14).

[0166] Example 3 confirmed that defects in melanosome transport occur in aged melanocytes.

[0167]

[0168] [Example 4]

[0169] Single-cell transcriptome reveals corresponding metabolic dysfunction in UVSM.

[0170] When cells are exposed to sublethal external stressors, such as UV irradiation, they can exhibit a variety of states in vitro. These states range from nearly normal cells to stressed cells, and ultimately, senescent cells. Therefore, in the present invention, we investigated changes in gene expression levels from nearly normal melanocytes to senescent melanocytes after UV irradiation. To achieve this at the single-cell level, we performed trajectory analysis based on single-cell RNA sequencing to analyze changes in gene expression levels and track the fate of melanocytes. Through this analysis, the inventors of the present invention aimed to identify "senescence driver" genes in melanocytes.

[0171] First, we identified six distinct subclusters (Fig. 15, left panel). Next, we performed pseudotime analysis of the cells, confirming that the aging module increased along the pseudotime trajectory (Fig. 15, right panel). Based on pseudotime, we named the clusters C1 to C6 according to the sequential increase in the aging module score (Figs. 15 and 16).

[0172] Referring to Figure 17, C4 was estimated to contain the most UV-responsive melanocytes, as indicated by the highest melanogenesis module scores (MITF, TYR, and TYRP1). Conversely, C5 and C6 showed a marked increase in CDKN2A gene expression. The inventors of the present invention further analyzed subclusters and found that senescence increased sequentially from C2 to C4 and from C4 to C5, while melanogenesis and melanocyte differentiation decreased at the transition point from C4 to C5.

[0173] To identify the molecular changes responsible for this increase in senescent gene expression, we evaluated differentially expressed genes (DEGs) between C2 / C4, C4 / C5, and C4 / C6. Therefore, we assigned C4 to senescent cells and C5 and C6 to fully senescent cells. The data above show that melanogenesis-related genes were downregulated in C5 and C6 compared to C4, as were melanin transport-related genes MYO5A, RAB27A, and MLPH (Figures 18 and 19). These data demonstrate that the gene expression patterns of fully senescent melanocytes and senescent melanocytes differ.

[0174] Therefore, the C4-to-C5 stage may be the most critical time point for determining whether melanocytes are senescent. Targeting this transition can inhibit or delay melanocyte senescence. Therefore, we analyzed key gene expression changes during the transition from C4 to C5, focusing on the expression levels of genes related to glycolysis signaling as key change factors (Fig. 20). The inventors of the present invention observed increased expression of a set of glycolysis genes in C5 and C6 (Fig. 21). We also observed a significant decrease in aerobic respiration and a significant increase in glycolysis in C5 compared to C4 (Figs. 22 and 23). C5 demonstrated upregulation of several genes related to glycolysis (in this case, HK1 and ENO1) compared to C4 (Fig. 22).

[0175] To confirm the upregulation of this process in aging melanocytes, glucose uptake and lactate production were examined in UVSM cases. These results showed that UVSM cells consumed twice as much glucose and produced 330% more lactate than controls (Figure 24).

[0176] In summary, Example 4 confirmed that this process is important for establishing senescence in melanocytes and consequently for the transport of defective melanosomes associated with aging.

[0177]

[0178] [Example 5]

[0179] Modulation of this metabolism alleviates melanocyte aging.

[0180] In addition to the single-cell RNA sequencing data described above, we confirmed that normal human melanocytes cultured under high glucose conditions (25 mM) exhibited higher p16INK4A expression levels associated with SA-β-Gal positivity and CDKN2A mRNA upregulation (Fig. 25), suggesting that changes in cellular glucose metabolism serve as a driving force for the induction of melanocyte senescence.

[0181] To assess the effect of glycolysis inhibition on melanocyte senescence, melanocytes were cultured with 0.5 mM 2-deoxyglucose (2-DG), a glycolysis inhibitor, for 24 h prior to UV stimulation. 2-DG, a glucose analogue, is known as a glycolysis inhibitor and the first key gatekeeper of glycolysis. Inhibition of glycolysis significantly downregulated the expression levels of senescence markers CDKN2A and CDKN1A (Fig. 27), as evidenced by reduced glucose consumption and lactate production in 2-DG-treated UVSM (Fig. 26). Furthermore, gene expression levels of IL-6, MMP1, and IGFBP7, which are senescence-associated secretory phenotype (SASP), were also downregulated (Fig. 28). Furthermore, fewer SA-β-Gal-positive cells were observed (Fig. 29), confirming that glycolysis inhibition mitigated melanocyte senescence.

[0182] Meanwhile, the levels of melanosome transport-related genes MYO5A, RAB27A, and MLPH were also restored in UVSM cells after 2-DG treatment (Fig. 30). Although no significant changes were observed in the expression levels of melanin-producing genes (MITF and TYR) (Fig. 31), melanin content was reduced by 2-DG treatment (Fig. 32). These data suggest that inhibition of this process by 2-DG restores the defective melanosome transport process in UVSM cells, thereby reducing melanin accumulation and melanosomes near the nucleus (Fig. 33).

[0183] In addition, when AZ67 (6-phosphofructo-2-kinase / fructose-2), a 6-bisphophatase 3 (PFKFB3) inhibitor, was used as an inhibitor of this process, the ability to delay melanocyte senescence was tested, and although the senescence markers of CDKN2A and CDKN1A were down-regulated, there was no significant change in the expression levels of melanosome transport-related genes and melanin production-related genes (Fig. 34).

[0184]

[0185] The above description of the present invention is for illustrative purposes only, and those skilled in the art will readily appreciate that the present invention can be readily modified into other specific forms without altering the technical spirit or essential characteristics of the present invention. Therefore, the embodiments described above should be understood as illustrative in all respects and not restrictive. For example, each component described as a single entity may be implemented in a distributed manner, and similarly, components described as distributed may be implemented in a combined manner.

[0186] The scope of the present invention is indicated by the claims described below rather than the detailed description above, and all changes or modifications derived from the meaning and scope of the claims and their equivalent concepts should be interpreted as being included in the scope of the present invention.

Claims

A composition for inhibiting skin aging, comprising 1.2-deoxy-D-glucose as an active ingredient.

2. In paragraph 1, The above 2-deoxy-D-glucose delays skin aging by inhibiting the aging of melanin cells in the skin. Composition for inhibiting skin aging.

3. In paragraph 2, The above 2-deoxy-D-glucose inhibits glycolysis. Composition for inhibiting skin aging.

4. In paragraph 3, The defect in the melanosome transport process is recovered by suppressing the above process. Composition for inhibiting skin aging.

5. In paragraph 1, The above 2-deoxy-D-glucose increases the expression of a melanosome transport-related gene selected from the group consisting of MYO5A, RAB27A, MLPH and combinations thereof. Composition for inhibiting skin aging.

6. In paragraph 1, The above 2-deoxy-D-glucose reduces the expression of cellular senescence-related genes selected from the group consisting of CDKN2A, CDKN1A, and combinations thereof. Composition for inhibiting skin aging.

7. In paragraph 1, The above 2-deoxy-D-glucose reduces the expression of a senescence-associated secretory phenotype (SASP) selected from the group consisting of IL-6, MMP1, IGFBP7 and combinations thereof. Composition for inhibiting skin aging.

8. In paragraph 1, A composition for inhibiting skin aging, wherein the composition for inhibiting skin aging further comprises a pharmaceutically acceptable carrier.

9. In paragraph 8, A composition for inhibiting skin aging, wherein the carrier comprises a selected from the group consisting of lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, menthol, mineral oil, and combinations thereof.

10. In paragraph 1, A composition for inhibiting skin aging, wherein the composition further comprises an ingredient selected from the group consisting of a preservative, a solubilizer, a stabilizer, a humectant, a sweetener, a colorant, a flavoring agent, a salt, a buffer, an antioxidant, a lubricant, an emulsifier, a suspending agent, a preservative, and combinations thereof.

11. In paragraph 1, The composition for inhibiting skin aging is administered by a method selected from the group consisting of intraperitoneal administration, oral administration, inhalation administration, intravenous administration, intramuscular administration, subcutaneous administration, dermal administration, intrauterine administration, tumor administration, rectal administration, and combinations thereof.

12. A health functional food comprising a composition for inhibiting skin aging according to Article 1.

Citation Information

Patent Citations

  • Use of an alkyl glycoside or of a mixture of alkyl glycosides having Anti-ageing properties as active agents in cosmetic compositions, and methods of cosmetic care using s ...

    KR1020090105875A

  • Pharmaceutical composition for inhibiting cancer recurrence or metastasis

    KR1020130015669A

  • Simple Phenolic Glycosidic Analogs, Method of Preparing the Same and Compositions for Skin-Lightening or Anti-Wrinkle Comprising the Same

    KR1020170051138A

  • Aroma diet sticker

    KR1020200087943A

  • Cylindrical structure gas cabinet equipped with sliding doors that can be opened and closed and secured from the risk of explosion by using tempered glass and a cutout provided on the upper part

    KR1020230018732A